IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
25.89
-0.28 (-1.07%)
Nov 20, 2026, 12:34 PM EST - Market open
IDEAYA Biosciences Employees
IDEAYA Biosciences had 145 employees as of December 31, 2025. The number of employees increased by 14 or 10.69% compared to the previous year. That makes IDEAYA Biosciences the 29,139th largest employer in the world and 3,670th in the United States.
Employees
145
Change (1Y)
14
Growth (1Y)
10.69%
Revenue / Employee
$251,972
Profits / Employee
-$2,896,641
Market Cap
2.50B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 145 | 14 | 10.69% | 145 | 0 |
| Dec 31, 2024 | 131 | 7 | 5.65% | 131 | 0 |
| Dec 31, 2023 | 124 | 21 | 20.39% | 124 | 0 |
| Sep 30, 2023 | 122 | 27 | 28.42% | 122 | 0 |
| Jun 30, 2023 | 116 | 25 | 27.47% | 116 | 0 |
| Mar 31, 2023 | 107 | 20 | 22.99% | 107 | 0 |
| Dec 31, 2022 | 103 | 22 | 27.16% | 103 | 0 |
| Sep 30, 2022 | 95 | 12 | 14.46% | 95 | 0 |
| Jun 30, 2022 | 91 | 16 | 21.33% | 91 | 0 |
| Mar 31, 2022 | 87 | 18 | 26.09% | 87 | 0 |
| Dec 31, 2021 | 81 | 19 | 30.65% | 81 | 0 |
| Sep 30, 2021 | 83 | 25 | 43.10% | 83 | 0 |
| Jun 30, 2021 | 75 | 29 | 63.04% | 75 | 0 |
| Mar 31, 2021 | 69 | 26 | 60.47% | 69 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Telix Pharmaceuticals | 1,184 |
| ADMA Biologics | 647 |
| Arcus Biosciences | 601 |
| Xencor | 260 |
| Celldex Therapeutics | 198 |
| Pharvaris | 168 |
| Celcuity | 155 |
IDYA News
- 4 hours ago - Ideaya Biosciences price target lowered to $55 from $62 at JPMorgan - TheFly
- 3 days ago - Ideaya Biosciences falls -11.8% - TheFly
- 3 days ago - IDEAYA Biosciences Transcript: Jefferies Global Healthcare Conference - Transcripts
- 3 days ago - Ideaya Biosciences reports on FDA Type C meeting on Phase 2/3 trial for IDE849 - TheFly
- 3 days ago - IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas - PRNewsWire
- 4 days ago - IDEAYA Biosciences Transcript: R&D Day 2026 - Transcripts
- 4 days ago - IDEAYA Biosciences Slides: FY 2026 - Filings
- 4 days ago - IDEAYA Biosciences Transcript: UBS Global Biopharma Conference 2026 - Transcripts